TITLE

HELSINN/BIOVITRUM SIGN LICENSE PACT FOR ALOXI MARKETING

PUB. DATE
April 2006
SOURCE
Worldwide Biotech;Apr2006, Vol. 18 Issue 4, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the license agreement signed by Helsinn Healthcare SA and Biovitrum AB which grants Biovitrum the exclusive license and distribution rights of Aloxi in the Nordic territory. Mechanism of action of Aloxi; Commercialization of the product in the U.S.; Background on Helsinn Healthcare and Biovitrum.
ACCESSION #
20374487

 

Related Articles

  • Eisai signs licensing agreement with Helsinn Healthcare.  // PharmaWatch: Cancer;Jul2010, Vol. 9 Issue 7, p18 

    The article reports on the licensing agreement signed between the U.S. subsidiary of Japanese company Eisai Inc. and Helsinn Healthcare SA for the commercialization of a new product for the prevention of chemotherapy-induced nausea and vomiting in the U.S. Covering the agreement will be the...

  • Exclusive rights on palonosetron. Tyler, Alan // European Chemical News;10/13/2003, Vol. 79 Issue 2072, p29 

    Reports that Schering-Plough Corp. has signed a license agreement with Swiss-based Helsinn Healthcare in October 2003 to develop and market Helsinn's palonosetron for the prevention of nausea and vomiting in chemotherapy patients. Component of the drug; Results from clinical trials of the drug.

  • Other News To Note.  // BioWorld International;6/16/2010, Vol. 15 Issue 24, p2 

    This section offers news briefs on the global biotechnology industry. Cytos Biotechnology Ltd. has sold its platform technology for the identification of monoclonal antibodies to Intercell AG. A license agreement was signed by Helsinn Healthcare SA with Eisai Inc. for the commercial rights to...

  • Biovitrum, Biogen Idec Eye 2011 Filing for Recombinant Factor IX. Sheridan, Cormac // BioWorld International;10/21/2009, Vol. 14 Issue 42, p1 

    The article reports on the plan of Biovitrum AB and Biogen Idec Inc. to use their long-acting Factor IX Fc fusion protein (rFIXFc) in a registration trial in hemophilia B patient in the first quarter of 2010. The disease is hereditary and caused by mutations in the gene encoding coagulation...

  • Safety Separation. Houlton, Sarah // Pharmaceutical Executive;Mar2005, Vol. 25 Issue 3, p46 

    Reports on the plan of the head of the European Agency for the Evaluation of Medicinal Products (EMEA) to have a separate safety agency from the authorities who approve drugs for marketing in Great Britain. Existence of potential development delays on the implementation of the plan; Likelihood...

  • Opinion: Lundbeck: Myriad deal is a high risk high reward strategy.  // PharmaWatch: CNS;Jul2008, Vol. 7 Issue 7, p4 

    The article provides an analysis regarding the move of H. Lundbeck A/S to acquire the European rights to Myriad Corp.'s Flurizan for the treatment of Alzheimer's disease. It is stated that Lundbeck is taking on a high risk investment with the deal because late stage failures are common in the...

  • Santarus Adds FENOGLIDE to Marketed Products Portfolio.  // Biomedical Market Newsletter;12/21/2011, Vol. 21, p1 

    The article offers information on an exclusive license agreement signed by Santarus Inc. with Shore Therapeutics Inc. The agreement was made to commercialize FENOGLIDE (fenofibrate) Tablets 40 mg and 120 mg in the U.S. Under the terms of the license agreement, Santarus will pay an 11 million...

  • APR Applied Pharma Research s.a. and Labtec GmbH Announce Ondansetron Oral Dispersible Film ("ODF") is Now Available for Licensing in Europe and Selected Non European Countries, after Having Received Marketing Authorization in Most Countries of Europe.  // Biomedical Market Newsletter;6/19/2011, p866 

    The article reports on the availability of Ondansetron Oral Dispersible Film (ODF) after Applied Pharma Research SA (APR) and Labtec GmbH have regained rights for marketing and commercialization of ODF. It states that ODF is available for licensing in Europe and selected non-European countries...

  • Proteus Digital Health Inc. and Otsuka Pharmaceutical Co. Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article informs that Proteus Digital Health Inc. and Otsuka Pharmaceutical Co. Ltd. have signed an exclusive license and collaboration agreement. The agreement has been made to develop and commercialize medicines based on Otsuka's pharmaceutical products and Proteus's digital health feedback...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics